A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06384807

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06384807. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Study identification

NCT ID: NCT06384807
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Enrollment: 500 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

BHV-1510 Drug
Cemiplimab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 22, 2024 (Actual)
Primary completion: Feb 2028 (Estimated)
Completion: Feb 2028 (Estimated)
Last update posted: Sep 28, 2026

2024 – 2028

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Site-113	Duarte	California	91010	Recruiting
Site-112	La Jolla	California	92093	Recruiting
Site-111	Palo Alto	California	94304	Recruiting
Site-114	Washington D.C.	District of Columbia	20016	Recruiting
Site-103	Miami	Florida	33176	Recruiting
Site-105	Orlando	Florida	32827	Recruiting
Site-115	Tampa	Florida	33612	Recruiting
Site-110	Augusta	Georgia	30912	Recruiting
Site-109	Detroit	Michigan	48201	Recruiting
Site-101	St Louis	Missouri	63108	Completed
Site-117	New York	New York	10021	Recruiting
Site-116	Oklahoma City	Oklahoma	73117	Recruiting
Site-108	Philadelphia	Pennsylvania	19107	Recruiting
Site-107	Nashville	Tennessee	37203	Recruiting
Site-104	Dallas	Texas	75231	Recruiting
Site-106	West Valley City	Utah	84119	Recruiting
Site-102	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06384807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2026 · Synced Nov 15, 2026